Alderuccio JP et al. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: A subgroup analysis from the LOTIS-2 study. Blood Adv 2022;6(16):4736-9. Abstract
Ansell S et al. Overall survival with brentuximab vedotin in Stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal Phase II study. ASH 2022;Abstract 610.
Batlevi CL et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of Symphony-1. ASH 2022;Abstract 954.
Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol 2022;23(8):1055-65. Abstract
Carlo-Stella C et al. Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R CHL). EHA 2022;Abstract S201.
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL Network. ASH 2022;Abstract 1.
Dreyling M et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. ASH 2022;Abstract 608.
Duell J et al. L-Mind: A safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years. ASH 2022;Abstract 2937.
Falchi L et al. Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial. ASH 2022;Abstract 611.
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update. ASH 2022;Abstract 609.
Fornecker L-M et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, Phase II trial. J Clin Oncol 2023;41(2):327-35. Abstract
Herrera AF et al. Exploratory analysis of factors influencing efficacy and safety of camidanlumab tesirine: Data from the open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ASH 2022;Abstract 1594.
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Kim TM et al. Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 949.
Kim W-S et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal Phase II study ELM-2. ASH 2022;Abstract 444.
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract
Morschhauser F et al. Six-year results from RELEVANCE: Lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. J Clin Oncol 2022;40(28):3239-45. Abstract
Nowakowski GS et al. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res 2022;28(18):4003-17. Abstract
Proudman DG et al. Tazemetostat in relapsed/refractory follicular lymphoma: A propensity score-matched analysis of E7438-G000-101 trial outcomes. Oncotarget 2022;13:677-83. Abstract
Ruan J et al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantle cell lymphoma. ASH 2022;Abstract 73.
Schuster M et al. Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL): A post-hoc analysis of the SADAL study. Clin Lymphoma Myeloma Leuk 2022;22(7):483-94. Abstract
Song Y et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study. Blood 2022;139(21):3148-58. Abstract
Spira A et al. Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2022;22(3):158-68. Abstract
Thieblemont C et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: A phase 2 study. EHA 2022;Abstract LB2364.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Townsend W et al. Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated FL: Final analysis of the GALLIUM study. EHA 2022;Abstract S206.
Wang M et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL): 2-year safety and efficacy analysis. ASH 2022;Abstract 2884.
Wang M et al. Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2. ASCO 2022;Abstract 7518.
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract